Table 1 Baseline demographic and medical characteristics

Age (years; N = 14)

58.8 (12.9)

64.2 (12.9)

55.8 (12.6)

.258

Sex (N = 14)

Male

10

4

6

.597

Female

4

1

3

Race (N = 14)

Caucasian

11

4

7

.923

African American

3

1

2

Education (N = 10)

High school or less

7

3

4

.490

Some post secondary school

3

2

1

Body mass index (kg/m²) (N = 14)

31.5 (7.4)

29.7(4.3)

33.4 (9.8)

.462

Smoking status (N = 14)

Never smoked

2

1

1

.375

Ex-smoker

8

4

4

Current smoker

2

0

2

Quit during treatment

2

0

2

Exercise at baseline (N = 11)

Exerciser

2

0

2

.114

Non-exerciser

9

5

4

MV exercise minutes^a

114.2 (232.1)

8 (11.0)

220.4 (304.9)

.158

Moderate exercise minutes^b

47.3 (79.1)

8 (11.0)

80 (98.0)

.140

Vigorous exercise minutes^c

6.4 (18.0)

0 (0)

11.7 (24.0)

.310

Number of comorbidities (N = 14)

1.7 (1.1)

2.2 (0.8)

1.2 (1.1)

.143

Type of lung cancer (N = 14)

Adenocarcinoma

5

1

4

Squamous

6

4

2

Large cell

1

0

1

Small Cell

1

0

1

NSCLC: Poorly differentiated

1

0

1

Stage (N = 14)

I

1

0

1

IIB

2

1

1

IIIA

8

2

6

IIIB

2

2

0

IV

1

0

1

Chemotherapy (N = 14)

Cisplatin/Irinotecan

7

2

5

Cisplatin/Pemetrexed

2

0

2

Carboplatin/Irinotecan

2

1

1

Paclitaxel/Bevacizum

1

1

0

Carboplatin/Pemetrexed

1

0

1

Taxol/Irinotecan

1

1

0

Radiation Therapy (N = 14)

None

1

1

0

50.4 Gy

1

0

1

60 Gy

4

1

3

66 Gy

7

3

4

PCI^d

1

0

1

Surgery (N = 14)

Inoperable

5

2

3

Preoperative

7

3

4

Postoperative

2

0

2